KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E Adjustments
Ratios

TherapeuticsMD (TXMD) Accumulated Depreciation & Amortization (2016 - 2023)

Historic Accumulated Depreciation & Amortization for TherapeuticsMD (TXMD) over the last 14 years, with Q3 2023 value amounting to $2.5 million.

  • TherapeuticsMD's Accumulated Depreciation & Amortization fell 1645.53% to $2.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.5 million, marking a year-over-year decrease of 1645.53%. This contributed to the annual value of $2.4 million for FY2022, which is 2404.87% up from last year.
  • TherapeuticsMD's Accumulated Depreciation & Amortization amounted to $2.5 million in Q3 2023, which was down 1645.53% from $2.5 million recorded in Q2 2023.
  • TherapeuticsMD's 5-year Accumulated Depreciation & Amortization high stood at $3.0 million for Q3 2022, and its period low was $115059.0 during Q2 2019.
  • For the 5-year period, TherapeuticsMD's Accumulated Depreciation & Amortization averaged around $1.8 million, with its median value being $2.1 million (2021).
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first plummeted by 7451.18% in 2019, then soared by 73412.26% in 2021.
  • Over the past 5 years, TherapeuticsMD's Accumulated Depreciation & Amortization (Quarter) stood at $612786.0 in 2019, then soared by 70.07% to $1.0 million in 2020, then skyrocketed by 89.12% to $2.0 million in 2021, then rose by 24.05% to $2.4 million in 2022, then grew by 2.37% to $2.5 million in 2023.
  • Its Accumulated Depreciation & Amortization was $2.5 million in Q3 2023, compared to $2.5 million in Q2 2023 and $2.5 million in Q1 2023.